What Is the Treatment of Heart Failure with Mildly Reduced Ejection Fraction?

Heart failure with mildly reduced ejection fraction (HFmrEF) requires a structured, evidence-based approach. The therapeutic goal is to reduce the risk of hospitalisation and cardiovascular mortality through targeted pharmacological management.

Treatment Approach

The regimen for HFmrEF includes a sodium-glucose cotransporter 2 inhibitor (SGLT2i) — the complete protocol, including sequencing and additional components, is available in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

In patients with HFmrEF, SGLT2i can be beneficial in decreasing HF hospitalizations and cardiovascular mortality.

DOI: 10.1161/CIR.0000000000001063

View source ↗